Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

YOSAFE TEMESGEN WAKWAYA

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1205275336
CMS profile
426088
Location
DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$1,196.51

53 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,115.65 52
Education $80.86 1

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

YOSAFE TEMESGEN WAKWAYA

NPI 1205275336 · CMS profile ID 426088

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1205275336?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
YOSAFE TEMESGEN WAKWAYA, NPI 1205275336, CMS profile ID 426088. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1205275336?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). YOSAFE TEMESGEN WAKWAYA, NPI 1205275336, CMS profile ID 426088. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1205275336?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
YOSAFE TEMESGEN WAKWAYA, NPI 1205275336, CMS profile ID 426088, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1205275336?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

53 matching records · $1,196.51 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 53 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–53 of 53.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $21.8101/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116264550 CMS
AstraZeneca Pharmaceuticals LP $14.8601/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105397448 CMS
AstraZeneca Pharmaceuticals LP $12.3201/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104689378 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $107.72 5
PY2022 $116.96 6
PY2023 $11,034.61 30
PY2024 $1,196.51 53
PY2025 $1,564.25 70

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $164,888.09 66
PY2024 Principal investigator $189,324.86 55
PY2023 Principal investigator $66,320.20 20
PY2022 Principal investigator $4,000.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

66 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 United Therapeutics Corporation $1,580.80 12/24/2025 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384169
Principal investigator 1 United Therapeutics Corporation $2,761.20 12/24/2025 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384181
Principal investigator 1 United Therapeutics Corporation $1,580.80 12/24/2025 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384205
Principal investigator 1 United Therapeutics Corporation $3,225.30 12/24/2025 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384217
Principal investigator 1 United Therapeutics Corporation $130.00 12/10/2025 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384147
Principal investigator 1 United Therapeutics Corporation $5,016.18 12/10/2025 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384229
Principal investigator 1 United Therapeutics Corporation $1,414.40 11/26/2025 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384167
Principal investigator 1 United Therapeutics Corporation $1,414.40 11/26/2025 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384203
Principal investigator 1 United Therapeutics Corporation $130.00 11/12/2025 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384145
Principal investigator 1 United Therapeutics Corporation $260.00 11/12/2025 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384153
Principal investigator 1 United Therapeutics Corporation $2,000.00 11/12/2025 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384175
Principal investigator 1 United Therapeutics Corporation $4,659.20 11/12/2025 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384195
Principal investigator 1 United Therapeutics Corporation $832.00 11/12/2025 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384199
Principal investigator 1 United Therapeutics Corporation $2,300.00 11/12/2025 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384209
Principal investigator 1 United Therapeutics Corporation $4,659.20 11/12/2025 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384223
Principal investigator 1 United Therapeutics Corporation $2,300.00 11/12/2025 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242384245
Principal investigator 1 United Therapeutics Corporation $1,918.00 10/29/2025 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242384237
Principal investigator 1 United Therapeutics Corporation $1,189.50 10/22/2025 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384161
Principal investigator 1 United Therapeutics Corporation $130.00 10/08/2025 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384143
Principal investigator 1 United Therapeutics Corporation $4,900.00 10/08/2025 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384227
Principal investigator 1 United Therapeutics Corporation $1,000.00 09/10/2025 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384159
Principal investigator 1 United Therapeutics Corporation $1,378.40 09/10/2025 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384163
Principal investigator 1 United Therapeutics Corporation $3,084.90 09/10/2025 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384187
Principal investigator 1 United Therapeutics Corporation $4,600.00 09/10/2025 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384221
Principal investigator 1 United Therapeutics Corporation $4,786.60 09/10/2025 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384225
Principal investigator 1 United Therapeutics Corporation $1,571.05 08/27/2025 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242384235
Principal investigator 1 United Therapeutics Corporation $130.00 08/13/2025 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384141
Principal investigator 1 United Therapeutics Corporation $19,301.10 08/01/2025 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242384253
Principal investigator 1 United Therapeutics Corporation $3,916.90 07/23/2025 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384189
Principal investigator 1 United Therapeutics Corporation $2,393.30 07/23/2025 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384211
Principal investigator 1 United Therapeutics Corporation $130.00 07/08/2025 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384139
Principal investigator 1 United Therapeutics Corporation $2,995.20 07/08/2025 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384185
Principal investigator 1 United Therapeutics Corporation $2,995.20 07/08/2025 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384215
Principal investigator 1 United Therapeutics Corporation $2,449.20 06/25/2025 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384177
Principal investigator 1 United Therapeutics Corporation $260.00 06/11/2025 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384151
Principal investigator 1 United Therapeutics Corporation $1,000.00 06/11/2025 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384157
Principal investigator 1 United Therapeutics Corporation $2,496.00 06/11/2025 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384179
Principal investigator 1 United Therapeutics Corporation $2,496.00 06/11/2025 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384213
Principal investigator 1 United Therapeutics Corporation $1,950.00 06/06/2025 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242384239
Principal investigator 1 United Therapeutics Corporation $2,300.00 06/06/2025 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242384243
Principal investigator 1 United Therapeutics Corporation $1,929.20 05/21/2025 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384173
Principal investigator 1 United Therapeutics Corporation $260.00 05/07/2025 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384149
Principal investigator 1 United Therapeutics Corporation $1,414.40 05/07/2025 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384165
Principal investigator 1 United Therapeutics Corporation $4,046.90 05/07/2025 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384191
Principal investigator 1 United Therapeutics Corporation $4,066.40 05/07/2025 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384193
Principal investigator 1 United Therapeutics Corporation $1,414.40 05/07/2025 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384201
Principal investigator 1 United Therapeutics Corporation $5,362.50 05/07/2025 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384231
Principal investigator 1 United Therapeutics Corporation $130.00 04/09/2025 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384137
Principal investigator 1 United Therapeutics Corporation $832.00 04/09/2025 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384155
Principal investigator 1 United Therapeutics Corporation $2,814.50 04/09/2025 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384183
Principal investigator 1 United Therapeutics Corporation $832.00 04/09/2025 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384197
Principal investigator 1 United Therapeutics Corporation $4,600.00 04/09/2025 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384219
Principal investigator 1 United Therapeutics Corporation $130.00 03/12/2025 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384131
Principal investigator 1 United Therapeutics Corporation $130.00 02/26/2025 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384123
Principal investigator 1 United Therapeutics Corporation $5,973.50 02/26/2025 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384129
Principal investigator 1 United Therapeutics Corporation $1,664.00 02/26/2025 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384171
Principal investigator 1 United Therapeutics Corporation $1,664.00 02/26/2025 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384207
Principal investigator 1 United Therapeutics Corporation $130.00 02/12/2025 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384125
Principal investigator 1 United Therapeutics Corporation $2,745.60 02/12/2025 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384127
Principal investigator 1 United Therapeutics Corporation $2,790.58 02/03/2025 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242384247
Principal investigator 1 United Therapeutics Corporation $3,958.50 02/03/2025 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242384249
Principal investigator 1 United Therapeutics Corporation $6,093.88 02/03/2025 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242384251
Principal investigator 1 United Therapeutics Corporation $2,393.30 01/29/2025 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384133
Principal investigator 1 United Therapeutics Corporation $2,745.60 01/29/2025 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384135
Principal investigator 1 United Therapeutics Corporation $832.00 01/08/2025 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242384233
Principal investigator 1 United Therapeutics Corporation $2,300.00 01/08/2025 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242384241